Diabetes, aging, and their tissue complications.
The inactivation of NO by advanced glycation endproducts (AGEs), which accumulate on tissue proteins as a function of age and hyperglycemia, focused attention on the role of these ubiquitous posttranslational modifications in acquired impairments of vascular reactivity and other signaling processes. This observation occurred during a watershed period of basic and translational research in glycation that encompassed new pathologic phenomena and novel intervention strategies. How has the AGE paradigm for the tissue complications of aging and diabetes fared since the identification of the link between these glycation products and NO inactivation, and what lessons may be offered for future investigations?
Rick
R
Bucala
D000375:Aging / Q000378:metabolism* / Q000473:pathology*; D003920:Diabetes Mellitus / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D009569:Nitric Oxide / Q000378:metabolism*
D017127:Glycation End Products, Advanced; D009569:Nitric Oxide